Skip to Main Content
TABLE 3

Correlates of Completion of Therapy, Univariate Analyses

VariableSubcategoryAll Patients (N = 667), No. (%)aCompleted (n = 591), No. (%)bDid Not Complete (n = 76), No. (%)bOR (95% CI)
Age (y) 0–<2 81 (12.1) 64 (79.0) 17 (21.0) Ref 
2–<5 148 (22.2) 128 (86.5) 20 (13.5) 1.7 (0.8–3.5) 
5–<10 158 (23.7) 141 (89.2) 17 (10.8) 2.2 (1.1–4.6) 
≥10 280 (42.0) 258 (92.1) 22 (7.9) 3.1 (1.6–6.2) 
Median (IQR) 8.0 (3.6–13.8) 8.3 (3.7–14.1) 5.1 (2.1–11.3) P = .002 
Sex Female 339 (50.8) 309 (91.2) 30 (8.8) Ref 
Male 328 (49.2) 282 (86.0) 46 (14.0) 0.6 (0.4–1.0) 
Race and/or ethnicity Hispanic 331 (49.6) 297 (89.7) 34 (10.3) Ref 
Asian 142 (21.3) 121 (85.2) 21 (14.8) 0.7 (0.4–1.2) 
Black 120 (18.0) 109 (90.8) 11 (9.2) 1.1 (0.6–2.3) 
White 72 (10.8) 62 (86.1) 10 (13.9) 0.7 (0.3–1.5) 
Multiracial 2 (0.3) 2 (100) P = .99 
Reason child tested for infection Foreign birth 330 (49.5) 284 (86.1) 46 (13.9) Ref 
Contact investigation 211 (31.6) 195 (92.4) 16 (7.6) 1.9 (1.1–3.6) 
Other 126 (18.9) 112 (88.9) 14 (11.1) 1.3 (0.7–2.5) 
Test of infection used TST alone 387 (58.0) 336 (86.8) 51 (13.2) Ref 
TST followed by IGRA 88 (13.2) 79 (89.8) 9 (10.2) 1.3 (0.6–2.8) 
IGRA alone 192 (28.8) 176 (91.7) 16 (8.3) 1.7 (0.9–3.0) 
How medications administered SAT 136 (20.4) 96 (70.6) 40 (29.4) Ref 
ESAT 35 (5.2) 29 (82.9) 6 (17.1) 2.0 (0.7–5.2) 
DOPT 496 (74.4) 466 (94.0) 30 (6.0) 6.5 (3.8–10.9) 
Regimen and manner of administration 9H, SAT 57 (8.5) 30 (52.6) 27 (47.4) Ref 
9H, ESAT 17 (2.5) 13 (76.5) 4 (23.5) 2.9 (0.9–10.1) 
9H, DOPT 178 (26.7) 158 (88.8) 20 (11.2) 7.1 (3.5–14.3) 
4R, SAT 79 (11.8) 66 (83.5) 13 (16.5) 4.6 (2.1–10.1) 
4R, ESAT 18 (2.7) 16 (88.9) 2 (11.1) 7.2 (1.5–34.2) 
4R, DOPT 35 (5.2) 34 (97.1) 1 (2.9) 30.6 (3.9–239) 
3HP 283 (42.4) 274 (96.8) 9 (3.2) 27.4 (11.8–63.7) 
VariableSubcategoryAll Patients (N = 667), No. (%)aCompleted (n = 591), No. (%)bDid Not Complete (n = 76), No. (%)bOR (95% CI)
Age (y) 0–<2 81 (12.1) 64 (79.0) 17 (21.0) Ref 
2–<5 148 (22.2) 128 (86.5) 20 (13.5) 1.7 (0.8–3.5) 
5–<10 158 (23.7) 141 (89.2) 17 (10.8) 2.2 (1.1–4.6) 
≥10 280 (42.0) 258 (92.1) 22 (7.9) 3.1 (1.6–6.2) 
Median (IQR) 8.0 (3.6–13.8) 8.3 (3.7–14.1) 5.1 (2.1–11.3) P = .002 
Sex Female 339 (50.8) 309 (91.2) 30 (8.8) Ref 
Male 328 (49.2) 282 (86.0) 46 (14.0) 0.6 (0.4–1.0) 
Race and/or ethnicity Hispanic 331 (49.6) 297 (89.7) 34 (10.3) Ref 
Asian 142 (21.3) 121 (85.2) 21 (14.8) 0.7 (0.4–1.2) 
Black 120 (18.0) 109 (90.8) 11 (9.2) 1.1 (0.6–2.3) 
White 72 (10.8) 62 (86.1) 10 (13.9) 0.7 (0.3–1.5) 
Multiracial 2 (0.3) 2 (100) P = .99 
Reason child tested for infection Foreign birth 330 (49.5) 284 (86.1) 46 (13.9) Ref 
Contact investigation 211 (31.6) 195 (92.4) 16 (7.6) 1.9 (1.1–3.6) 
Other 126 (18.9) 112 (88.9) 14 (11.1) 1.3 (0.7–2.5) 
Test of infection used TST alone 387 (58.0) 336 (86.8) 51 (13.2) Ref 
TST followed by IGRA 88 (13.2) 79 (89.8) 9 (10.2) 1.3 (0.6–2.8) 
IGRA alone 192 (28.8) 176 (91.7) 16 (8.3) 1.7 (0.9–3.0) 
How medications administered SAT 136 (20.4) 96 (70.6) 40 (29.4) Ref 
ESAT 35 (5.2) 29 (82.9) 6 (17.1) 2.0 (0.7–5.2) 
DOPT 496 (74.4) 466 (94.0) 30 (6.0) 6.5 (3.8–10.9) 
Regimen and manner of administration 9H, SAT 57 (8.5) 30 (52.6) 27 (47.4) Ref 
9H, ESAT 17 (2.5) 13 (76.5) 4 (23.5) 2.9 (0.9–10.1) 
9H, DOPT 178 (26.7) 158 (88.8) 20 (11.2) 7.1 (3.5–14.3) 
4R, SAT 79 (11.8) 66 (83.5) 13 (16.5) 4.6 (2.1–10.1) 
4R, ESAT 18 (2.7) 16 (88.9) 2 (11.1) 7.2 (1.5–34.2) 
4R, DOPT 35 (5.2) 34 (97.1) 1 (2.9) 30.6 (3.9–239) 
3HP 283 (42.4) 274 (96.8) 9 (3.2) 27.4 (11.8–63.7) 

IQR, interquartile range; REF, reference for subgroup analyses.

a

Percentages for each subgroup are within the column; percentages may not sum to 100% because of rounding.

b

Percentages are within the row.

Close Modal

or Create an Account

Close Modal
Close Modal